

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to the Approval for Drug Registration of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

27 May 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Approval for Drug Registration of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement, or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Jinzhou Avanc Pharmaceutical Company Limited* (錦州奧鴻藥業有限責任公司), and Liaoning Children Pharmaceutical Co., Ltd* (遼寧兒童製藥有限公司), subsidiaries of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the “**Company**” and, together with its subsidiaries/units, the “**Group**”), recently received the approval for drug registration from the National Medical Products Administration for the Desloratadine Oral Solution (the “**New Drug**”), which is used for the alleviation of systemic and local symptoms of chronic idiopathic urticaria and allergic rhinitis.

II. General Information of the New Drug

Generic Name: Desloratadine Oral Solution

Dosage Form: Oral Solution

Specification: 60ml:30mg

Registration Category: Chemicals Category 3

Marketing Authorization Holder: Liaoning Children Pharmaceutical Co., Ltd

Pharmaceutical Manufacturer: Jinzhou Avanc Pharmaceutical Company Limited

Drug Approval Number: Guo Yao Zhun Zi H20243788

III. Research and Marketing Progress of the New Drug

The New Drug is a chemical drug independently developed by the Group, which is intended to be used primarily for the alleviation of systemic and local symptoms of chronic idiopathic urticaria and allergic rhinitis

As of April 2024, the Group has invested approximately RMB8.17 million (unaudited) in total in the research and development of the New Drug at the current stage.

As at the date of this announcement, in addition to the New Drug, other Desloratadine products which have been approved to be launched in China (excluding Hong Kong, Macau, and Taiwan Region for the purpose of this announcement, the same applies below) mainly include Fubiding* (芙必叮®) of Hainan Poly Pharm Co. Ltd.* (海南普利製藥股份有限公司), Baixinha* (百新哈®) of Wan Te Pharmaceutical (Hainan) Company Limited* (萬特製藥(海南)有限公司), and Desloratadine syrup of Sichuan Chengdu Tongdaotang Pharmaceutical Co. Ltd.* (四川成都同道堂製藥有限責任公司). According to the latest data from IQVIA CHPA¹, the sales of the Desloratadine products in China in 2023 amounted to approximately RMB315 million.

IV. Impact on the Listed Company and Risk Warning

The approval for marketing registration of the New Drug will bring more options for the medication for chronic idiopathic urticaria and allergic rhinitis and will further enrich the product line of the Group. It is expected that the approval of the New Drug will not have a material impact on the Group's results at this stage.

Due to the characteristics of the pharmaceutical products industry, the specific sales performance of pharmaceutical products after launch may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, and is subject to considerable uncertainty. Investors should take note of the investment risks.

¹ Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data represents the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

27 May 2024

** For identification purposes only*